Hospital

Heidi Finnes, PharmD, BCOP, FHOPA, discusses the evolving landscape of treatment for patients with cutaneous malignancies and melanoma.

A review of the requirements for pharmacies considering ordering compounds from a 503B facility.

Multiple sclerosis is a debilitating disease affecting many Americans. Pharmacists can help patients control the symptoms that impact their quality of life.

The recent approval could further the use of mRNA technology across other indications.

Rose DiMarco, PharmD, BCPS, BCOP, shares insights into the evolving treatment landscape for patients with breast cancer with specific mutations.

The supplemental new drug application (sNDA) for brexpiprazole is accepted by the FDA for treatment of patients with post-traumatic stress disorder (PTSD).

Jordyn P. Higgins, PharmD, BCOP, discusses the evolving treatment landscape for small cell lung cancer (SCLC).

Adagrasib receives accelerated approval for patients with previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC).

Compared to placebo, nicotinamide riboside significantly improved the 6-minute walking capabilities in patients with decreased endurance and muscle function due to peripheral artery disease.

The quadruplet regimen added bortezomib to the current standard of care, which is a triplet regimen of isatuximab, lenalidomide, and dexamethasone for patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM TI).

There are numerous challenges with cell and gene therapies in oncology, such as accessibility, cost, and prior authorizations, as well as the need for improved education and training within the oncology community.

Tim Mok, PharmD, BCOP, BCPS, discusses innovative therapies that are changing the treatment options available for patients with hematologic malignancies.

Additionally, the high cost of the cell therapy raises concerns for broader access.

Adopting the Planetary Health Diet may reduce overall risk of chronic disease and premature death.

Reducing maternal mortality through improving access, screening, education and providing support during pregnancy.

Study shows that orange peel extract may reduce risk of heart disease and adverse cardiovascular events.

V116 (Capvaxive; Merck) elicited higher immune responses than the comparator for the serotypes that are unique to the vaccine, according to studies submitted to the FDA.

The FDA approved blinatumomab for treatment of patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Durvalumab plus carboplatin and paclitaxel, continued with durvalumab monotherapy, decreased the risk of disease progression or death by 58%.

Mim8 had a safe and well-tolerated profile, with no deaths or thrombotic events reported for patients with hemophilia A.

Data show that among individuals 60 years and older, the estimated rate of Guillain-Barré syndrome (GBS) after receiving an RSV vaccine was 5.0 and 1.5 per million doses of Abrysvo and Arexvy, respectively.

Amplification of chromosome 1q is associated with poorer treatment outcomes for patients with relapsed/refractory and newly diagnosed multiple myeloma.

With the new ruling, announced Thursday, the pills will continue to be able to be mailed to patients without an in-person visit with a physician.1

At ASHP Pharmacy Futures 2024, Mei T. Liu, PharmD, BCPP, highlights the global prevalence and multifaceted nature of depression, its bidirectional relationship with medical conditions, and the need for diverse, evidence-based treatment options.

Lindsey P. Sheehan, PharmD, MPA, MBA, discusses ongoing challenges of diagnosing and treating hepatitis C, emphasizing its increased incidence among younger populations and ongoing low rates of diagnosis.

A 1-time infusion of valoctocogene roxaparvovec had demonstrated sustained bleed control and factor VIII expression in patients with hemophilia A.

Speakers at American Society of Health-System Pharmacists (ASHP) Pharmacy Futures 2024 discuss the significant increase in published clinical literature during and after the COVID-19 pandemic, and the evolving role and reliability of AI tools such as ChatGPT in providing accurate medical information.

Donanemab was able to significantly slow clinical progression of Alzheimer disease and amyloid and tau pathology at 76 weeks of treatment.